Navigation Links
Interim Clinical Trial Results Confirm Safety of Renadyl™, a Probiotic Dietary Supplement for the Support of Healthy Kidney Function
Date:3/8/2012

NEWTOWN SQUARE, Pa., March 8, 2012 /PRNewswire/ -- On the occasion of World Kidney Day, Kibow Biotech, Inc. is pleased to announce that interim data from an expanded clinical trial of Renadyl™ (http://www.Renadyl.com) confirms the positive results for safety and improved quality of life (QOL) previously established in a pilot-scale study for kidney failure patients. The probiotic microbial strains in the product formulation are "Generally Recognized As Safe" ("GRAS - status") as per US FDA regulations.

Renadyl™, originally marketed under the registered name of Kibow® Biotics, is a probiotic dietary supplement which is currently being tested to determine its ability to help reduce the build-up of uremic toxins, and thus help maintain healthy kidney function.

Following-up on the encouraging results obtained in a multisite, pilot-scale study with chronic kidney disease (CKD) Stage III and IV patients, the Company is actively sponsoring an expanded study of Renadyl™, administered at higher dosage levels to both predialysis and dialysis patients. These clinical trials, which began in April of 2011, are being performed at Thomas Jefferson University, Philadelphia, PA, Downstate Medical Center (State University of New York) and at Kings County Hospital in Brooklyn, NY. More information is available at http://www.clinicaltrials.gov, under Kibow Biotech Inc - (NCT 01450670, 01450657 and 01450709).

About Kibow Biotech

Founded in 1997, Kibow Biotech specializes in research and development of probiotic dietary supplements. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health. The Company's flagship product, Renadyl™, is currently marketed in the US and Canada, and will progressively be made available worldwide, according to individual c
'/>"/>

SOURCE Kibow Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
4. LPBP Inc. - Re-filing certification of interim filings
5. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
6. Arpida Reports Interim Results for Six Months to 30 June 2008
7. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
8. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
9. Misonix Announces Interim Distribution Agreement for Italy
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014 Tigercat Pharma, ... 2 study evaluating the investigational oral NK-1 receptor ... with severe, chronic itch who are unresponsive or ... including topical steroids and antihistamines. ... Visual Analog Scale (VAS) itch score from baseline, ...
(Date:12/15/2014)... , Dec. 15, 2014 Organovo Holdings, ... company focused on delivering breakthrough 3D bioprinting technology,  ... and collaborators of its exVive3D TM Human ... available in full commercial release on November 18, ... resulting in several awards for innovation. ...
(Date:12/13/2014)... N.C. (PRWEB) December 13, 2014 CanDiag, ... Charlotte) spin-out company has changed its name to OncoTab, ... accurate representation of where we are today,” said CEO ... extended our platform’s applications beyond breast cancer diagnostics to ... a reflection of that evolution.” , Founded in 2011 ...
(Date:12/13/2014)... USA, and TAICHUNG, Taiwan (PRWEB) December 12, 2014 ... despite less rosy indicators in overall global economic growth, ... for optics and photonics , said in a featured ... Conference) on 5 December at the National Chung Hsing ... energy, which is being integrated into future energy supplies ...
Breaking Biology Technology:Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5
... NewLink Genetics Corporation today announced that additional data from ... HyperAcute® Pancreas cancer immunotherapy will be presented during a ... 2011 Gastrointestinal Cancers Symposium in San Francisco, California. A ... Title: Effect of the addition of algenpantucel-L immunotherapy to ...
... ROCKVILLE, Md., Jan. 20, 2011 OriGene Technologies, Inc. ... for developing an assay for every human protein through ... TrueMAB brand. Each TrueMAB antibody is specifically developed with ... for critical research and diagnostic needs requiring improved antibody ...
... Inc. (Nasdaq: RDEA ) today announced the ... 2,750,000 shares of its common stock, offered at a ... gross proceeds to Ardea from this offering are expected ... and other estimated offering expenses payable by Ardea.  BofA ...
Cached Biology Technology:NewLink Genetics to Present Phase 2 Data of Its HyperAcute® Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers Symposium 2NewLink Genetics to Present Phase 2 Data of Its HyperAcute® Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers Symposium 3NewLink Genetics to Present Phase 2 Data of Its HyperAcute® Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers Symposium 4OriGene Releases 1500 TrueMAB™ Monoclonal Antibodies 2Ardea Biosciences Prices Public Offering of Common Stock 2Ardea Biosciences Prices Public Offering of Common Stock 3
(Date:12/17/2014)... FORT BELVOIR, Va. , Dec. 15, 2014 ... its efforts to make it easier to detect ... supply chain. Today the agency started ... marking. The capability will validate the authenticity of ... supply chain. The new quality control measures will ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays a ... while. Hypertension – the medical term for high blood pressure ... 1800s, and the inflatable cuff that,s used in measuring blood ... mean there,s nothing new about hypertension, its triggers and its ... about the condition and the best ways to treat it. ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... A new University of Florida study shows ecologists may ... than 150 years. The study featured on the cover ... bone remains provide high-quality geographical data across an extensive time ... habitat for the conservation of threatened species. Charles ...
... 2012) Tufts University School of Engineering researchers have ... improvement in tissue imaging while simultaneously enabling photo ... delivery. The devices also lend themselves to a ... and biocompatible, these tiny mirror-like devices dissolve harmlessly ...
... NY Bread wheat ( Triticum aestivum ) is one ... of the calories consumed by people. Fully 35% of the ... survival. Now an international team of scientists, including a group ... comprehensive analysis of its full genome. The study ...
Cached Biology News:UF researcher tests powerful new tool to advance ecology, conservation 2UF researcher tests powerful new tool to advance ecology, conservation 3Implantable silk optics multi-task in the body 2Bread wheat's large and complex genome is revealed 2Bread wheat's large and complex genome is revealed 3
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... C-terminus of Human MSY2/YBOX2. (Note: ... (Peptide available as ...
SAPK/JNK Antibody...
Biology Products: